Partner Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$60M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Partner Therapeutics's estimated annual revenue is currently $33.5M per year.(i)
  • Partner Therapeutics received $60.0M in venture funding in February 2018.
  • Partner Therapeutics's estimated revenue per employee is $155,000
  • Partner Therapeutics's total funding is $60M.

Employee Data

  • Partner Therapeutics has 216 Employees.(i)
  • Partner Therapeutics grew their employee count by 8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

WE'RE ALL IN FOR FIGHT AGAINST CANCER Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients. We are united in our passion for improving the treatment of cancer and our desire to make a meaningful contribution to outcomes. THE PATIENT IS NUMBER ONE We believe that being a cancer company begins and ends with the patient. We strive to support patient needs throughout their treatment journey to help them make the treatment choices that are right for them and their loved ones. FIGHTING CANCER IS TEAM SPORT We believe that cancer is a complex, dynamic disease that requires a multi-faceted, multi-disciplinary approach to tackle. We believe in teamwork at each stage of a therapy's development, and seek to build teams of experts, both internally and externally, that cover the breadth and depth of the complex problem that is cancer. We work with leading companies and investigators to ensure that our products are tested in the best settings, and in combination with highest potential regimens to maximize benefit to patients and to advance the understanding of cancer treatment. We seek to engage all members of the cancer treatment team as well as thought-leading physicians and patient advocacy organizations to ensure that clear, complete and balanced information about our products is proactively communicated and readily available. We work to support the extraordinary dedication of the medical teams that represent the front lines in the war on cancer. OUTCOMES ARE OUR YARDSTICK We believe that innovation is not enough. In the challenging world of today's healthcare climate, we strive to develop and assess our products based on the real-world impact they have in improving the quality and duration of our patients lives. We measure our success in the birthdays, anniversaries and other important life moments that our patients are able to enjoy.

keywords:N/A

$60M

Total Funding

216

Number of Employees

$33.5M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Partner Therapeutics News

2022-03-30 - Study: Preclinical Mouse Model Shows Cognitive Improvement in ...

Partner Therapeutics, based in Lexington, Massachusetts, has teamed up with the University of Colorado to study mouse models of Down...

2022-03-22 - Radiation exposure drug maker says it is ramping up supply in Europe

One drugmaker, Partner Therapeutics, isn't waiting to take action. The company said it is helping to ramp up supply in Europe of Leukine,...

2022-03-22 - Partner Therapeutics Announces Publication of Results from Pre ...

Partner Therapeutics Announces Publication of Results from Pre-Clinical Study Evaluating Recombinant Murine GM-CSF in Mouse Models of Down...

2021-05-19 - Partner Therapeutics Announces Publication of Clinical Trial Results of Leukine® (sargramostim) in Patients with Parkinson's Disease

LEXINGTON, Mass., May 19, 2021 /PRNewswire/ --Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT03790670) evaluating the use of Leukine® (sargramostim, yeast-derived rhuGM-CSF) in patients with ...

2021-03-24 - Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer's Disease

LEXINGTON, Mass., March 24, 2021 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT01409915) evaluating the use of Leukine® (sargramostim, yeast-derived rhuGM-CSF) in patients w ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$52.5M21715%N/A
#2
$32.8M218-3%$155.7M
#3
$58.3M21818%N/A
#4
$43.2M218-8%N/A
#5
$50.4M218-3%N/A

Partner Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-02-02$60.0MAAdams Street PartnersArticle